Edward J. Dulac III - 06 Feb 2023 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Financial Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
06 Feb 2023
Net transactions value
$0
Form type
4
Filing time
07 Feb 2023, 15:15:19 UTC
Previous filing
11 Jan 2023
Next filing
06 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +425,000 $0.000000 425,000 06 Feb 2023 Common Stock 425,000 $6.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.